Search

Coloplast A-S (Class B)

Gesloten

578.2 1.12

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

576.8

Max

579.6

Belangrijke statistieken

By Trading Economics

Inkomsten

70M

875M

Verkoop

2M

7B

K/W

Sectorgemiddelde

35.807

90.831

EPS

3.88

Dividendrendement

4.01

Winstmarge

12.572

Werknemers

16,744

EBITDA

2B

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

+11.86% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

4.01%

2.20%

Volgende Winsten

6 feb 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

7.5B

130B

Vorige openingsprijs

577.08

Vorige sluitingsprijs

578.2

Coloplast A-S (Class B) Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

16 jan 2026, 23:29 UTC

Populaire aandelen

Stocks to Watch: Atossa Therapeutics, Union Pacific

17 jan 2026, 15:06 UTC

Acquisities, Fusies, Overnames

Trump Purchased Netflix, Warner Bonds in Days After Deal Announcement -- Update

17 jan 2026, 03:10 UTC

Acquisities, Fusies, Overnames

Trump Purchased Netflix, Warner Bonds In Days After Deal Announcement -- WSJ

16 jan 2026, 22:48 UTC

Acquisities, Fusies, Overnames

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- 2nd Update

16 jan 2026, 22:43 UTC

Acquisities, Fusies, Overnames

Union Pacific: Additional Information Requested to Be Provided to Surface Transportation Board

16 jan 2026, 22:22 UTC

Acquisities, Fusies, Overnames

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- Update

16 jan 2026, 21:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Tech, Media & Telecom Roundup: Market Talk

16 jan 2026, 21:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Auto & Transport Roundup: Market Talk

16 jan 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

16 jan 2026, 21:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

16 jan 2026, 21:48 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Union Pacific, Norfolk Southern Market Share Ruled as Faulty -- Market Talk

16 jan 2026, 21:41 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Union Pacific, Norfolk Southern Deal Rejection Leaves Questions -- Market Talk

16 jan 2026, 21:38 UTC

Acquisities, Fusies, Overnames

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- WSJ

16 jan 2026, 21:30 UTC

Acquisities, Fusies, Overnames

STB: Union Pacific, Norfolk Southern Application Doesn't Include 'Projected Market Shares' as Required

16 jan 2026, 21:30 UTC

Acquisities, Fusies, Overnames

STB: Union Pacific, Norfolk Southern Application Doesn't Include Certain Schedules, Documents Expressly Made Part of Merger Agreement

16 jan 2026, 21:30 UTC

Acquisities, Fusies, Overnames

STB: Union Pacific, Norfolk Southern Application Doesn't Contain Certain Information Required by Regulations

16 jan 2026, 21:30 UTC

Acquisities, Fusies, Overnames

STB: Application Rejected Without Prejudice to Union Pacific, Norfolk Southern Refiling Revised Application Remedying Deficiencies

16 jan 2026, 21:30 UTC

Acquisities, Fusies, Overnames

Surface Transportation Board: Union Pacific, Norfolk Southern Major Merger Application Filed Dec. 19 Incomplete

16 jan 2026, 20:44 UTC

Winsten

5 Takeaways From This Season's Wealth Management Earnings -- Barrons.com

16 jan 2026, 20:42 UTC

Marktinformatie

Oil Futures Post Fourth Straight Weekly Gain -- Market Talk

16 jan 2026, 20:28 UTC

Marktinformatie

U.S. Natural Gas Slips Ahead of Long Weekend -- Market Talk

16 jan 2026, 19:12 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Netflix Could Comment on Structure of Warner Bid During 4Q Results -- Market Talk

16 jan 2026, 18:53 UTC

Marktinformatie

Global Crude Supply Enough to Absorb Any Iran Disruption -- Market Talk

16 jan 2026, 18:41 UTC

Marktinformatie

Netflix's Ad Business Seen as Primary Revenue Driver in 2026 -- Market Talk

16 jan 2026, 18:31 UTC

Marktinformatie

U.S. Oil Rig Count Rises By 1 to 410 -- Market Talk

16 jan 2026, 17:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

16 jan 2026, 17:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

16 jan 2026, 17:20 UTC

Marktinformatie

Health Care Roundup: Market Talk

16 jan 2026, 17:03 UTC

Marktinformatie

Global Equities Roundup: Market Talk

16 jan 2026, 17:03 UTC

Marktinformatie

All Eyes on Guidance for European Big Pharma Earnings Season -- Market Talk

Coloplast A-S (Class B) Prognose

Koersdoel

By TipRanks

11.86% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 901.38 DKK  11.86%

Hoogste 1,056 DKK

Laagste 720 DKK

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Coloplast A-S (Class B) - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

8 ratings

2

Buy

4

Hold

2

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
help-icon Live chat